The Biden administration's Medicare Advantage proposals aim to maintain stability in an election year. A Democrat's support for legislation weakening Medicare's drug price negotiation power contrasts with the administration's efforts to negotiate lower drug costs. The Inflation Reduction Act, passed without House GOP votes, has capped monthly insulin costs for Medicare recipients, resulting in significant annual savings. The FDA's potential increased White House control under a second Trump term and the Biden administration's historic negotiations to make 10 drugs cheaper for Medicare highlight partisan divides. The administration is considering overriding patent rights to address pricey drugs, and negotiations over high-cost drugs mark a milestone for Democrats. Biden administration officials are engaging pharmacy executives to address Paxlovid costs.
Exclusive: Biden admin officials push pharmacy execs on Paxlovid costs https://t.co/sv2amiZVdy @TreedinDC
In a milestone for Democrats, the Biden administration last week kicked off negotiations over the first set of 10 high-cost drugs. • If Trump wins a second term, he could weaken negotiations on Medicare drug pricing. https://t.co/95Dpp2tD5V
Biden administration considers overriding patent rights to address pricey drugs @LouisaMoller reports. https://t.co/KZaSXxffCr
In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the months ahead, including key deadlines, meetings, events, planned regulations, comment periods and more. Read here: https://t.co/wItvZwtCJh #AgencyIQ #Politico #Regulation #FDA https://t.co/2gN9E8ArbI
For the first time in history the Biden admin has begun negotiating to make 10 drugs cheaper for Medicare. This is a watershed event and one that every single republican in Congress voted against. https://t.co/rIf0NzVvWd
For your election radar ... #Pinksheet #pharma: Gottlieb: @US_FDA Would Be Subject To More White House Control Under A Second Trump Term https://t.co/owR9RX0ADq
In 2022 I helped pass the Inflation Reduction Act — without a single vote from the @HouseGOP. This groundbreaking legislation capped monthly insulin costs at $35 a month for Medicare recipients — now NW Ohio Seniors are seeing a $480 annual savings on their insulin costs. https://t.co/U4RNXTzDvs
A Democrat was willing to sign on to legislation that would weaken Medicare's power to negotiate drug prices, a key Biden achievement. https://t.co/FQ9psJEwMJ
The big takeaway from CMS’ newest proposals for Medicare Advantage: the Biden administration didn’t want to rock the boat in an election year. Read the new edition of Health Care Inc. https://t.co/nGAx16eZap